Project Grant R33HL187253
Award Date 8/15/26
Completion Date 5/31/28
Dollars Obligated $446K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,924 on July 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837) to support research on cell surface localization of Factor VIII mimetic therapy for hemophilia A treatment. The award funds a five-year project running through June 30, 2031, with work performed in Chapel Hill, North Carolina. The research addresses hemophilia A, an inherited bleeding disorder caused...
- The National Heart Lung and Blood Institute awarded North Carolina State University $698,083 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop hemostatic B-knob triggered microgels that leverage age-dependent clotting mechanisms for treating pediatric trauma-associated hemorrhage. The project addresses life-threatening bleeding in pediatric trauma patients, where hemorrhagic shock is a common cause of death. Current treatment relies on...
- The National Heart Lung and Blood Institute awarded $655,564 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop SPARKS-DCM, a multiscale computational modeling framework that integrates biochemistry, biophysics, and biomechanics of blood clotting with experimental data to predict mechanisms of action for procoagulant agents in platelet integrin disorders such as Glanzmann's thrombasthenia. The...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $165,260 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research on the role of the small GTPase Rap1 and environmental cues in regulating adhesion and cytoskeletal dynamics in migrating platelets. The research addresses molecular mechanisms underlying platelet migration at sites of inflammation, with potential applications to immunothrombosis...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded Stasys Medical Corp $325,648 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish ISO 13485–compliant manufacturing for test cartridges supporting the ATLAS platelet function diagnostic platform. The project delivers a scalable production line for single-use test cards containing microfluidic chips with shear-activating force sensors designed to detect platelet micro-clots. Work includes...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung and Blood Institute awarded the University of Washington $1,601,223 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to combine large-scale experiments and computational modeling to dissect how variants in the F9 gene affect coagulation factor IX (FIX) secretion, carboxylation, activation, and disease pathogenesis. The research addresses the clinical challenge of interpreting variants of uncertain significance (VUS) in hemophilia B...